Phase 2 Again Shown Effective in Weight Loss Trial

The study found that those in the supplement group lost significantly more body weight and waist girth at the end of the first 30 days and at the end of the trial than did those in the placebo group.

Jul 30 2010 --- Results of a new study appearing in the Journal of Applied Research has validated yet again that consumption of Phase 2 Carb Controller, a specialized extract of a fraction of the  white bean, assists significantly in weight loss.
 
Entitled “Enhanced Weight Loss from a Dietary Supplement Containing Standardized Phaseolus vulgaris Extract in Overweight Men and Women,” the study found that those in the supplement group lost significantly more body weight and waist girth at the end of the first 30 days and at the end of the trial than did those in the placebo group. Additionally, the BMI decreased significantly more after the first and second month in the supplement group compared to the placebo group.
 
The 101 subject, 60-day protocol included an active group of 51 subjects who consumed the supplements and a placebo group of 50 subjects. At the onset, body weight, waist and hip circumferences, and blood chemistry values were measured; these measurements were also taken at 30 days, and at the end of the 60-day trial. BMI was calculated taking weight and height into consideration.
 
The results showed that 47 of 51 subjects in the supplement group lost weight (92%) after two months, compared to 31 in the placebo group (62%). The average weight loss in the supplement group was 1.9 kg compared to a 0.4 kg loss in the placebo group.
 
“The Phase 2 group lost nearly five times more weight than the placebo group,” said Mitch Skop, senior director of new product development for Pharmachem Laboratories Inc., the developer and manufacturer of Phase 2.  “The waist size also decreased significantly more in the supplement group; 1.9cm vs. -0.4cm, another five-fold difference.”
 
“The results of this study is yet another clear and compelling validation of the efficacy, safety and economy—of Phase 2 as a tool in achieving healthy weight loss,” added Skop.

According to the researchers, the mechanism behind the weight loss associated with consuming this bean extract “relies on alpha-amylase-inhibiting activity. Phaseolus vulgaris extract has been shown in vitro to inhibit the activity of alpha-amylase and may help promote weight loss by interfering with the digestion of complex carbohydrate to simple, absorbable sugars, potentially reducing carbohydrate-derived calories. Before crossing the intestinal wall, all complex carbohydrates (i.e., starches) must be hydrolyzed to their monosaccharide units, in most cases glucose. There are several enzymes involved in this process – alpha-amylase present in saliva and pancreatic juice, which converts complex carbohydrate into oligosaccharides, and various other enzymes (maltase, lactase, etc.) present in the brush border of the small intestine that convert these oligosaccharides to monosaccharides that can then be absorbed.”
 
This is the 30th scientific citation in the Phase 2 dossier, available on request.